Pfizer Inc PFE

$29.79 -0.24 (-0.80%)

Valuation

Market cap
171,161,200,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.97
Forward PE
10.33
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
25,656,300
Avg volume
32,104,324
Day's range
$29.72 – $30.31
Shares out
5,699,674,000
Stochastic %K
66%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Fliptax Oct 27, 12:27 PM
$PFE https://finance.yahoo.com/healthcare/articles/pfizer-elrexfio-outperforms-standard-regimens-104500090.html $JNJ $MRNA $LLY
0 replies
TopOptionAlert Oct 27, 12:19 PM
$PFE NOV20 31C · still actionable Zone: $29.49 to $29.90 Invalidation: close under $28.54 Objectives: $31.50, then $33.50 The math: up 6.1% to the first objective and 12.8% to the second, against 3.9% risk on the invalidation, better than 3 to 1 to the second. Dear friend, picture a drug maker sitting just under its high for the year, with good news piling up and its next report only a week away. Pfizer closed Monday at 29 dollars and 79 cents, near the top of its yearly range, after winning a wider approval for its prostate cancer pairing and reporting strong Phase 3 results for its blood cancer medicine. This swing is simply a bet that buyers keep paying up into the November 3 report, toward 31 dollars and 50 cents and then toward 33 dollars and 50 cents, while a close under 28 dollars and 54 cents says the strength gave way and you step aside. P.S. Watch 30 dollars and 44 cents, the high for the year, because a close over it leaves only fresh ground ahead.
0 replies
Agent8 Oct 27, 11:50 AM
$PFE Red to Green
0 replies
Agent8 Oct 27, 11:46 AM
$PFE https://finance.yahoo.com/healthcare/articles/pfizer-elrexfio-outperforms-standard-regimens-104500090.html
0 replies
zMIMI Oct 27, 11:43 AM
$PFE Got to love Pfizer! A successful Phase 3 trial for Elrexfio, and it doesn't even seem to show up in pre-market trading! The MagnetisMM-32 trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma.
1 replies
Outcomes Oct 27, 11:39 AM 0 replies
Parlandoconme Oct 27, 10:29 AM
$TOMZ wonder if ray will ever reveal his cost basis on this stock? we ask him everyday and he never answers. he probably works for a competitor? $PFE
0 replies
Quantumup Oct 27, 9:22 AM
Citizens reiterated $IDYA Market Outperform-$42 after the Co's ESMO presentation. $IMCR $PFE NVS REPL MRK ESAIY AMGN AZN AABBV DSNKY ZLAB Citizens said in its note: IDEAYA Biosciences presented three updates across the emerging darovasertib franchise: novel data in HLA-A*02 positive mUM, from the neoadjuvant setting in OptimUM-09, and sub-group analyses from the pivotal OptimUM-02 study in HLA-A*02 negative mUM. While darovasertib generated mOS in the HLA-A*02-positive subgroup that was on par with the HLA-A2-negative subgroup in treatment-naïve patients, darovasertib also proved that there is some level of efficacy in 2L+ patients and could support its use post-tebentafusp. Doctor feedback was positive.
0 replies